About Cyrus Biotechnology
Cyrus Biotechnology is a company based in Seattle (United States) founded in 2014. Cyrus Biotechnology has raised $31.99 million across 11 funding rounds from investors including HHS, Orbimed and Trinity Ventures. The company has 23 employees as of December 31, 2022. Cyrus Biotechnology has completed 1 acquisition, including Orthogonal Biologics. Cyrus Biotechnology offers products and services including IdeS, IL-22 Variant, and sACE2.v2-Fc. Cyrus Biotechnology operates in a competitive market with competitors including Vividion Therapeutics, Seer, Biognosys, ProteinSimple and NiKang Therapeutics, among others.
- Headquarter Seattle, United States
- Employees 23 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cyrus Biotechnology Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$31.99 M (USD)
in 11 rounds
-
Latest Funding Round
$300 K (USD), Grant
Dec 20, 2024
-
Investors
HHS
& 10 more
-
Employee Count
23
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cyrus Biotechnology
Cyrus Biotechnology offers a comprehensive portfolio of products and services, including IdeS, IL-22 Variant, and sACE2.v2-Fc.
Protein for IgG depletion in autoimmune diseases.
Fusion protein for gastrointestinal and metabolic conditions.
Candidate for COVID-19 prophylaxis in immunocompromised individuals.
People of Cyrus Biotechnology
Unlock access to complete
Unlock access to complete
Funding Insights of Cyrus Biotechnology
Cyrus Biotechnology has successfully raised a total of $31.99M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $300 thousand completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cyrus Biotechnology
Cyrus Biotechnology has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Orbimed and Trinity Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in early-stage technology and real estate companies.
|
Locked | Locked | Locked | |
|
Agent Capital is focused on healthcare venture capital investments.
|
Locked | Locked | Locked |
Investor details for Cyrus Biotechnology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cyrus Biotechnology
Cyrus Biotechnology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Orthogonal Biologics.
Investment portfolio details for Cyrus Biotechnology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Protein drug manufacturing and research services are provided.
|
Locked | Locked | 2020 | Locked |
Complete acquisition details for Cyrus Biotechnology
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Cyrus Biotechnology
Detailed financials for Cyrus Biotechnology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cyrus Biotechnology Comparisons
Peer comparison for Cyrus Biotechnology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cyrus Biotechnology
Cyrus Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vividion Therapeutics, Seer, Biognosys, ProteinSimple and NiKang Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| Locked | Locked | Locked |
Proteomics services are delivered via discovery and targeted platforms.
|
|
| Locked | Locked | Locked |
Provider tools to help researchers with protein analysis
|
|
| Locked | Locked | Locked |
Small molecule oncology therapeutics are developed for cancer treatment.
|
Detailed competitors of Cyrus Biotechnology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cyrus Biotechnology
Complete news archive for Cyrus Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cyrus Biotechnology
Cyrus Biotechnology was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Cyrus Biotechnology is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Cyrus Biotechnology is a funded company, having raised a total of $31.99M across 11 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Cyrus Biotechnology is 23.
Cyrus Biotechnology was founded in 2014 in Seattle, United States, within the biotechnology sector. Cloud-based software for protein modeling in drug discovery is provided. The primary product, Cyrus Bench, is offered as a modified version of the open-source Rosetta molecular modeling tool. This is bundled with essential bio-molecular computation resources, including BLAST, and features a custom user interface to support full utilization.
Cyrus Biotechnology's top competitors include Vividion Therapeutics, Biognosys and NiKang Therapeutics.
Cyrus Biotechnology offers IdeS, IL-22 Variant, and sACE2.v2-Fc.
Cyrus Biotechnology has made 1 acquisition, including Orthogonal Biologics.
Cyrus Biotechnology has 11 investors. Key investors include HHS, Orbimed, Trinity Ventures, Agent Capital, and Alumni Ventures.